Dedifferentiation of Epithelial Cells Incorporates Immune Reprogramming

Ying Ma; Jihui Hao

doi:10.1016/j.tcb.2021.01.007

Dedifferentiation of Epithelial Cells Incorporates Immune Reprogramming

Trends Cell Biol. 2021 Apr;31(4):237-240. doi: 10.1016/j.tcb.2021.01.007. Epub 2021 Feb 13.

Authors

Ying Ma¹, Jihui Hao²

Affiliations

¹ Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Electronic address: yingma@tmu.edu.cn.
² Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Electronic address: haojihui@tjmuch.com.

PMID: 33593679
DOI: 10.1016/j.tcb.2021.01.007

Abstract

Recent innovations in immunotherapies have cured cancers but remain ineffective in pancreatic cancer, which exhibits intertwined dynamics of dedifferentiation of epithelium and reprogramming of immunosuppression. Emerging evidence reveals the biological mechanisms through which dedifferentiation recapitulates immune reprogramming, providing new insights into the therapeutic potential of controlling dedifferentiation for sensitization to immunotherapies.

Keywords: dedifferentiation; extracellular communication; immunosuppression; pancreatic ductal adenocarcinoma (PDAC).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Pancreatic Ductal*
Epithelial Cells
Humans
Immunotherapy
Pancreatic Neoplasms*